MedTrace Logo

Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

NCT03986918 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-06-14

No results posted yet for this study

Summary

The objective of this study is to evaluate patient outcomes in regards to safety and effectiveness based on the clinical performance of the reference devices to further support the assessment of residual risk identified in the Clinical Evaluation Report for the Ortho Development Hip System.

Conditions

Interventions

DEVICE

Routine Total Hip Arthroplasty

Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.

Sponsors & Collaborators

  • Ortho Development Corporation

    lead INDUSTRY

Principal Investigators

  • Cass Nakasone, MD · Hawai'i Pacific Health

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2023-06-30
Completion
2024-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986918 on ClinicalTrials.gov